The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells
Open Access
- 1 May 2011
- journal article
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 22 (9), 1463-1472
- https://doi.org/10.1091/mbc.e10-11-0877
Abstract
Transforming growth factor-β (TGF-β) plays an important role in regulating hematopoiesis, inhibiting proliferation while stimulating differentiation when appropriate. We previously demonstrated that the type III TGF-β receptor (TβRIII, or betaglycan) serves as a novel suppressor of cancer progression in epithelial tumors; however, its role in hematologic malignancies is unknown. Here we demonstrate that TβRIII protein expression is decreased or lost in the majority of human multiple myeloma specimens. Functionally, restoring TβRIII expression in myeloma cells significantly inhibited cell growth, proliferation, and motility, largely independent of its ligand presentation role. In a reciprocal fashion, shRNA-mediated silencing of endogenous TβRIII expression enhanced cell growth, proliferation, and motility. Although apoptosis was not affected, TβRIII inhibited proliferation through induction of the cyclin-dependent kinase inhibitors p21 and p27. TβRIII further regulated myeloma cell adhesion, increasing homotypic myeloma cell adhesion while decreasing myeloma heterotropic adhesion to bone marrow stromal cells. Mechanistically, live cell imaging of myeloma and stroma cell cocultures revealed that TβRIII-mediated inhibition of heterotropic adhesion was associated with decreased duration of myeloma/bone marrow stromal cell interaction. These results suggest that loss of TβRIII expression during multiple myeloma progression contributes to disease progression through its functional effects on increased cell growth, proliferation, motility, and adhesion.Keywords
This publication has 46 references indexed in Scilit:
- The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42Proceedings of the National Academy of Sciences, 2009
- Type III Transforming Growth Factor-β (TGF-β) Receptor Mediates Apoptosis in Renal Cell Carcinoma Independent of the Canonical TGF-β Signaling PathwayClinical Cancer Research, 2008
- Bone Morphogenetic Proteins Signal through the Transforming Growth Factor-β Type III ReceptorJournal of Biological Chemistry, 2008
- Expression of the type III TGF-β receptor is negatively regulated by TGF-βCarcinogenesis: Integrative Cancer Research, 2008
- Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-κB and C/EBPβBlood, 2007
- Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and InvasionCancer Research, 2007
- The type III TGF-β receptor suppresses breast cancer progressionJCI Insight, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- The molecular classification of multiple myelomaBlood, 2006
- A Novel Mechanism for Regulating Transforming Growth Factor β (TGF-β) SignalingJournal of Biological Chemistry, 2001